OverviewSuggest Edit

Natera (formerly known as Gene Security Network) is a genetic testing company that operates a CLIA-certified laboratory. The company offers a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; a single-gene mutation screening test to identify single-gene disorder; a carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier’s children.

TypePublic
Founded2004
HQSan Carlos, CA, US
Websitenatera.com
Employee Ratings4
Overall CultureD

Latest Updates

Employees (est.) (Dec 2019)1,039(+7%)
Job Openings220
Revenue (FY, 2020)$391 M(+30%)
Share Price (Jul 2021)$116.8
Cybersecurity ratingBMore

Key People/Management at Natera

Steve Chapman

Steve Chapman

Chief Executive Officer and Director
Mike Brophy

Mike Brophy

Chief Financial Officer
Matthew Rabinowitz

Matthew Rabinowitz

Executive Chairman, Co-Founder
Jonathan Sheena

Jonathan Sheena

Chief Technology Officer, Co-Founder
Robert Schueren

Robert Schueren

Chief Operating Officer
Olesya Anisimova

Olesya Anisimova

Senior Vice President, Financial Controller
Show more

Natera Office Locations

Natera has an office in San Carlos
San Carlos, CA, US (HQ)
201 Industrial Rd
Show all (1)

Natera Financials and Metrics

Natera Revenue

Natera's revenue was reported to be $391.01 m in FY, 2020
USD

Revenue (Q1, 2021)

152.3m

Net income (Q1, 2021)

(63.9m)

EBIT (Q1, 2021)

(63.0m)

Market capitalization (22-Jul-2021)

10.3b

Closing stock price (22-Jul-2021)

116.8

Cash (31-Mar-2021)

65.1m

EV

10.6b
Natera's current market capitalization is $10.3 b.
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

217.1m210.9m257.7m302.3m391.0m

Revenue growth, %

14%(3%)22%

Cost of goods sold

135.6m139.6m166.1m

Gross profit

81.5m71.3m91.6m
Quarterly
USDQ1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Revenue

46.9m53.6m56.7m62.3m63.1m65.3m66.8m74.4m77.9m94.0m86.5m98.1m152.3m

Cost of goods sold

33.7m34.6m34.6m39.1m39.2m39.5m43.3m43.8m43.9m41.5m42.7m

Gross profit

13.2m19.1m22.0m23.3m23.9m25.8m23.5m30.5m34.0m52.5m43.7m

Gross profit Margin, %

28%36%39%37%38%40%35%41%44%56%51%
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

15.3m12.6m46.4m61.9m48.7m

Accounts Receivable

13.4m8.3m62.2m53.4m78.6m

Prepaid Expenses

7.1m8.6m6.2m16.4m26.6m

Inventories

6.4m9.0m13.6m12.4m20.0m
Quarterly
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(95.8m)(136.3m)(128.2m)(124.8m)(229.7m)

Depreciation and Amortization

6.2m7.1m7.5m7.7m8.6m

Inventories

(2.1m)(3.1m)(4.9m)917.0k(7.5m)

Accounts Payable

1.3m217.0k3.8m(6.3m)(118.0k)
USDFY, 2016

Revenue/Employee

254.8k

Debt/Equity

0.5 x

Debt/Assets

0.2 x

Financial Leverage

2 x
Show all financial metrics

Natera Operating Metrics

Q1, 2016Q2, 2016Q3, 2016FY, 2016Q1, 2017Q2, 2017Q3, 2017FY, 2017Q1, 2018Q2, 2018Q3, 2018FY, 2018Q1, 2019Q2, 2019Q3, 2019

Countries Covered

618181

Covered Lives

200 m200 m200 m203 m195 m198 m198 m208 m200 m205 m205 m209 m209 m209 m209 m

Laboratory Distribution Partners

7070707070707090909090100100100100

Tests

105 k209 k318 k447 k121 k247.1 k377.5 k515.2 k164.36 k327.16 k494.33 k668.6 k200.19 k394.66 k594.88 k
Show all operating metrics

Natera Acquisitions / Subsidiaries

Company NameDateDeal Size
Natera International, Inc.

Natera Revenue Breakdown

Embed Graph

Natera revenue breakdown by business segment: 6.7% from Licensing and Other and 93.3% from Genetic Tests

Natera revenue breakdown by geographic segment: 8.1% from Europe, Middle East, India, Africa, 87.7% from United States and 4.2% from Other

Natera Cybersecurity Score

Cybersecurity ratingPremium dataset

B

81/100

SecurityScorecard logo

Natera Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

Natera Online and Social Media Presence

Embed Graph

Natera Company Culture

  • Overall Culture

    D

    62/100

  • CEO Rating

    C+

    68/100

  • Compensation

    D+

    60/100

  • Diversity

    D

    56/100

Learn more on Comparably

Natera News and Updates

Natera Reports Preliminary Second Quarter 2021 Results

AUSTIN, Texas, July 19, 2021 /PRNewswire/ -- Natera, Inc. (Nasdaq: NTRA) ("Natera" or the "Company"), a pioneer and global leader in cell-free DNA testing, today reported preliminary results for the quarter ended June 30, 2021 for volume and revenue growth. The Company's revenue growth...

How To Develop A Company While Transforming Your Industry: A Case Study With Natera

MedTech research and technology has transformed the standard of care, and changed how the industry understands DNA testing

Can Natera Stock Rebound After A 14% Fall In A Week?

The stock price of Natera, a clinical genetic testing company, has seen a large 14% drop in just five trading sessions. The decline is driven in part by the broader sell-off in high growth stocks, and profit booking at higher levels. Note that NTRA stock rallied 5x from $25 levels seen in March...

Natera Implements First Wave of Panorama® AI Improvements With Immediate Impact on Patient Experience and COGS

AUSTIN, Texas, April 7, 2021 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, has implemented the first wave of Panorama AI innovations following the breakthrough results shared earlier from the SMART study. Panorama AI is a new algorithm...

Natera Reports Third Quarter 2020 Financial Results

SAN CARLOS, Calif., Nov. 5, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today reported financial results for the third quarter ended September 30, 2020 and provided an update on recent business progress. Recent Accomplishments &...

Natera Receives Final Medicare Coverage for its Signatera™ MRD Test in Stage II-III Colorectal Cancer

SAN CARLOS, Calif., Sept. 3, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that the CMS Molecular Diagnostics Program (MOLDX) has finalized a local coverage determination (LCD) to provide Medicare benefits for...
Show more

Natera Blogs

Advances in Donor-Derived cfDNA Testing – Promising New Data in Simultaneous Pancreas-Kidney Transplants

The post Advances in Donor-Derived cfDNA Testing – Promising New Data in Simultaneous Pancreas-Kidney Transplants appeared first on Natera.

Cancer Immunotherapy Awareness Month

The post Cancer Immunotherapy Awareness Month appeared first on Natera.

Empowering Melanoma Risk Assessment

The post Empowering Melanoma Risk Assessment appeared first on Natera.

Lessons Learned from Screenings Delayed During COVID-19

The post Lessons Learned from Screenings Delayed During COVID-19 appeared first on Natera.

Why Screening for Lynch Syndrome is Important

The post Why Screening for Lynch Syndrome is Important appeared first on Natera.

New Study Sheds Light on Racial Barriers to Hereditary Cancer Screening

The post New Study Sheds Light on Racial Barriers to Hereditary Cancer Screening appeared first on Natera.
Show more

Natera Frequently Asked Questions

  • When was Natera founded?

    Natera was founded in 2004.

  • Who are Natera key executives?

    Natera's key executives are Steve Chapman, Mike Brophy and Matthew Rabinowitz.

  • How many employees does Natera have?

    Natera has 1,039 employees.

  • What is Natera revenue?

    Latest Natera annual revenue is $391 m.

  • What is Natera revenue per employee?

    Latest Natera revenue per employee is $376.3 k.

  • Who are Natera competitors?

    Competitors of Natera include Invitae, Illumina and Progenity.

  • Where is Natera headquarters?

    Natera headquarters is located at 201 Industrial Rd, San Carlos.

  • Where are Natera offices?

    Natera has an office in San Carlos.

  • How many offices does Natera have?

    Natera has 1 office.